The PMHNP is managing a patient with treatment-resistant schizophrenia who continues to have positive symptoms despite appropriate trials with two different antipsychotic regimens. When considering initiation of clozapine, the NP considers that which of the following apply?  

A. The absolute neutrophil count must be > 1000/mm3 to start treatment 

B. The first 2-3 doses should be administered in a closely monitored setting with vital signs monitored regularly

C. The medication must be ministered in accordance with the FDA REMS  safety monitoring 

D. The medication has significantly less medication interaction potential as compared to other antipsychotics 

---

YouTube: https://www.youtube.com/watch?v=GH7CZF80ghI&list=PLf0PFEPBXfq5HGfNV-GbOlYHtDwd35OeG&index=130





Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Fitzgerald Health Education Associates. Innehållet i podden är skapat av Fitzgerald Health Education Associates och inte av, eller tillsammans med, Poddtoppen.